BiomX Inc.: management transactions · United States · SEC (Form 4)

About BiomX Inc.

BiomX Inc. is a United States-listed company trading on the NYSE American market under the ticker PHGE, and it has historically been best known as a phage- and microbiome-focused biotechnology company. For investors in France, Belgium, and Switzerland, it fits the profile of a small-cap, high-risk biotech with meaningful clinical, regulatory, and financing risk. The company was founded out of the FutuRx incubator with support from the Israel Innovation Authority, and it built its original platform around the discovery and development of therapies targeting specific pathogenic bacteria. Its operating roots are in Israel, with a historical headquarters in Ness Ziona. BiomX’s core business, in its original form and still reflected in its public communications, centers on developing natural and engineered phage cocktails designed to treat diseases driven by specific bacterial targets. The company has disclosed programs across acne, inflammatory bowel disease, oncology-related applications, and microbiome modulation approaches. This is the classic structure of an advanced-stage platform biotech: value creation depends on scientific differentiation, intellectual-property protection, clinical execution, and the ability to fund development long enough to generate meaningful readouts. From a competitive standpoint, BiomX operates in a crowded field that includes specialist biotech peers, major pharmaceutical companies, and emerging microbiome/phage-therapy platforms. Its position is determined less by current scale than by the quality of its pipeline, the strength of its data package, and the credibility of its partnering potential. In markets like this, investors typically focus on proof-of-concept results, regulatory strategy, and whether the company can secure non-dilutive collaborations or strategic financing. Recent public disclosures indicate a major strategic pivot. In 2026, BiomX announced an agreement to acquire a controlling stake in DFSL, an Israeli laser-radar (LADAR) security and defense technology company focused on perimeter security, critical infrastructure, and counter-UAS applications. That move is highly material for the equity story because it broadens the company beyond healthcare into security and defense technology, potentially changing revenue prospects, capital allocation priorities, and the overall risk-return profile. For US-listed shareholders, the key items to watch are SEC Form 4 insider transactions, financing activity, and whether BiomX can convert its scientific and technology assets into sustainable shareholder value.